Skip to main content

Table 2 Antiretroviral therapy prior to nevirapine-containing regimen

From: Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children

PATIENT AGE at 1st regimen Mono-therapy Dual-therapy Cumulative duration HAART Cumulative duration CD4% Viral load cop/ml
  months NRTI NRTI NRTI PI PI 0–12 months 0–12 months
      D4T-3TC- AMP(36 m)+   
1 119 NO ZDV-DDI 27 AMP+RIT RIT (6 m) 33–41 50–50
2 39 NO ZDV-DDI 36 D4T-3TC-AMP AMP(48 m) 32–30 50–50
3 65 NO NO 0 ZDV-DDI-RIT RIT(32 m) 29–34 50–50
4 14 ZDV ZDV-DDI 19+21 D4T-3TC-NFV NFV(56 m) 42–44 50–50
5 92 NO NO 0 ZDV-ABC-IND IND(28 m) 34–30 50–50
6 9 ZDV/DDI NO 109 ZDV-DDI-IND IND(60 m) 32–27 50–10325
7 6 ZDV NO 92 ZDV-3TC-IND IND(52 m) 31–34 50–50
        33%(29,42)  
median 53 m (6,119)    52 m (0,109) 130 m (99,177) 47 m (28,60) 37%(27,44) 50
  1. NRTI: nucleoside reverse transcriptase inhibitor, ZDV: zidovudine, DDI: dianosine, D4T: stavudine, 3TC: lamivudine; PI: protease inhibitor, AMP: amprenavir, RIT: ritonavir, NFV: nefinavir, IND: indinavir; m: months; cop/ml: copies/ml (HIV-RNA, liner range: 50–500.000 cop/ml)